Abbott Laboratories Cash Flow from Operating Activities 2010-2025 | ABT
Abbott Laboratories annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2025. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Abbott Laboratories cash flow from operating activities for the quarter ending March 31, 2025 was $1.417B, a 38.24% increase year-over-year.
- Abbott Laboratories cash flow from operating activities for the twelve months ending March 31, 2025 was $18.650B, a 25.55% increase year-over-year.
- Abbott Laboratories annual cash flow from operating activities for 2024 was $8.558B, a 17.86% increase from 2023.
- Abbott Laboratories annual cash flow from operating activities for 2023 was $7.261B, a 24.21% decline from 2022.
- Abbott Laboratories annual cash flow from operating activities for 2022 was $9.581B, a 9.04% decline from 2021.
| Abbott Laboratories Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2024 | $8,558 |
| 2023 | $7,261 |
| 2022 | $9,581 |
| 2021 | $10,533 |
| 2020 | $7,901 |
| 2019 | $6,136 |
| 2018 | $6,300 |
| 2017 | $5,570 |
| 2016 | $3,203 |
| 2015 | $2,966 |
| 2014 | $3,675 |
| 2013 | $3,324 |
| 2012 | $9,314 |
| 2011 | $8,970 |
| 2010 | $8,736 |
| 2009 | $7,275 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $231.085B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||